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The management of large bone defects due to trauma, degenerative disease, congenital deformities, and tumor resection remains
a complex issue for the orthopaedic reconstructive surgeons. The requirement is for an ideal bone replacement which is
osteoconductive, osteoinductive, and osteogenic. Autologous bone grafts are still considered the gold standard for reconstruction
of bone defects, but donor site morbidity and size limitations are major concern. The use of bioartiﬁcial bone tissues may help to
overcome these problems. The reconstruction of large volume defects remains a challenge despite the success of reconstruction of
small-to-moderate-sized bone defects using engineered bone tissues. The aim of this paper is to understand the principles of tissue
engineering of bone and its clinical applications in reconstructive surgery.
1.Introduction
Boneisahighlyvascularisedtissuethatconstantlyundergoes
remodellingasaresultofthebalancebetweentheactivitiesof
the osteoclasts and the osteoblasts, which allows adaptation
to mechanical stresses, maintenance of bone health, and
repair of small injuries. A recent study demonstrated that
the coupling between osteoclastic bone resorption and
osteoblastic bone formation is needed for bone homeostasis
[1]. Because of the potential of bone to spontaneously
regenerate, most small bone lesions, such as fractures, heal
well with conventional therapy or surgery. During bone
repair, the osteogenic process, under the inﬂuence of bone-
derived bioactive factors, commences after the inﬂammatory
phase and is initiated by precursor cells from the periosteum
adjacent to the fracture site. This generates hard callus
by intramembranous bone formation. An autologous bone
graft or bone substitute is often required to assist in the
healing of an extensive traumatic or postsurgical bone defect
and of osseous congenital deformities. The majority of bone
formation, however, is by enchondral ossiﬁcation of the soft
callus that appears after inﬁltrated mesenchymal cells are
induced to chondrogenesis. This improved understanding of
repair, and regeneration has helped with the development of
orthopaedic tissue engineering [2].
Historically, a variety of substitutes like celluloid, alu-
minium, gold, vitallium, tantalum, stainless steel, tita-
nium, methyl methacrylate resins, polyethylene, silicone
elastomers, and hydroxyapatite ceramics have been tried
[3]. The main concerns with the use of these synthetic
materials for bone reconstruction were their inability to
vascularise, integrate, and undergo remodelling. This may
result in structural failure of the implant under load or
pathological changes in the surrounding bone, as seen in
stress shielding [4]. The other issues are inﬂammatory
scarring, neoproliferative reaction in the adjacent tissues and
infection [5]. Because of their high osteoinductive potential
and remodelling characteristics, bioactive substitutes such as
demineralized bone matrix (allogeneic or xenogeneic) have
shown promise, despite risk of disease transmission, as well
as cost and availability [6]. This led to the evolution of tissue
engineering techniques (biologically enhanced allografts,
cell-based therapies, and gene-based therapies) to treat bone
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Tissue engineering has been deﬁned as the application
of scientiﬁc principles to the design, construction, modiﬁ-
cation, and growth of living tissue using biomaterials, cells,
and factors alone and in combination [7]. It involves the use
ofosteoconductivebiomaterialscaﬀolds,withosteogeniccell
populations and osteoinductive bioactive factors. The three
components for tissue regeneration are (1) a degradable
support or scaﬀold material; (2) bioactive factors, such as
growth factors; (3) cells. The potential for bone tissue engi-
neeringtherapiesinclinicalapplicationsisexempliﬁedbythe
clinical success of recombinant human bone morphogenetic
protein-2 for the treatment of fractures [8].
The most promising primary tissue engineering strate-
gies are (1) isolation of mesenchymal stems cells (MSCs),
their ex vivo expansion, and seeding onto a scaﬀold to
produce extracellular matrix (ECM) on the scaﬀold; (2)
implantation of an acellular scaﬀold into the osseous defect
[7]. Translation of this technology into practice requires
an additional surgical procedure and the time lag for the
bone graft to develop in vitro. A variety of novel ex vivo
culture techniques have been designed to speed up the
cellular production of ECM. Three principal ex vivo culture
techniques utilized in bone tissue engineering are growth
factor delivery, bioreactor systems, and gene therapy.
2. Stem Cells
A stem cell is a cell from the embryo, fetus, or adult that,
under certain conditions, can reproduce for long periods.
It can also give rise to specialized cells of body tissues and
organs. The use of stem cells from the embryo or fetus
has many ethical considerations, whereas the use of adult
stem cells is generally well accepted by society. An adult
stem cell is an undiﬀerentiated or unspecialized cell present
in diﬀerentiated tissue, which renews itself and becomes
specialized to yield all of the cell types of the tissue from
which it originated. Their progeny includes both new stem
cells and committed progenitors with a more restricted
diﬀerentiation potential. These progenitor cells in turn
give rise to more diﬀerentiated cell types. The advantages
of using stem cells rather than diﬀerentiated cells are a
higher proliferative capacity, a higher regenerative potential
over time, and the ability to allow revascularization of the
avascular scaﬀold. Cells with osteoprogenitor features have
beenisolatedfromseveraltissuesincludingperiosteum,bone
marrow, adipose tissue, and retina. The choice of source
depends on accessibility, frequency of cells, and information
of a particular cell system.
The sources of osteogenic human cells are primary cells,
MSCs, embryonic stem cells, and induced pluripotent stem
cells. We use cells after considering various factors like
proliferation potential, osteogenicity, vasculogenicity, the
homogeneity, and the phenotype stability, as well as cell
safety after implantation. Diﬀerentiation of these cells can
be obtained in vitro by changing the culture conditions
after their expansion or by providing a new physiological
microenvironmentinthetransplantareainvivo.Theprocess
involves the isolation of cells, with expansion in vitro culture
and enrichment of appropriate cell type for enhanced bone
formation, integration of the cells with host tissues, and
expression of stable osteogenic phenotype.
Primary osteogenic cells can be derived from adult
bone tissue and periosteum [9–14]. Due to donor site
morbidity [15–17] and limited proliferation of primary
cells, preparation of large autologous grafts from primary
bone or periosteum-derived cells would be diﬃcult [18–
20]. Research suggests that stem cells derived from bone
marrow (BMSC) can be expanded for a signiﬁcant number
of cell doublings without cell senescence. The bone marrow
is a reservoir of multipotent stem cells for mesenchymal
tissues that can diﬀerentiate into ﬁbroblastic, osteogenic,
adipogenic, and reticular cells [21]. Expansion of stem cells
using bone marrow aspirates depends on the donor age,
volume, and technique. Although, it has been demonstrated
that BMSCs can be culture expanded to large numbers [21],
the osteogenic potential of BMSCs is maintained in older
individuals [22], and appropriate conditions in vitro (e.g.,
culture on collagen substrate and growth factor supplemen-
tation of culture media) [23, 24] can help maintain cell
diﬀerentiation potential [25, 26].
Adiposetissuestemcells(ASCs),duetotheiraccessibility
and potential for diﬀerentiation into osteogenic cells, repre-
sent another attractive source for bone tissue engineering.
The number of cells produced by expansion is inﬂuenced by
the tissue harvesting procedure, as well as the site of tissue
harvesting, for example, arm, thigh, abdomen, and breast
[27, 28]. ASCs undergo similar mesenchymal lineage speciﬁc
diﬀerentiation as BMSC. They also display similar surface
antigen. The principle advantages of ASCs use are that they
exist in abundant numbers, can be obtained with minimal
donor morbidity, their proliferative capacity is unaﬀected by
age, and they have the ability to regenerate bone in critical
sized bone defects [29, 30].
Takahashi and Yamanaka [31] described the use of
induced pluripotent stem (IPS) cells. The main concern in
their conceptualisation was the risk of viral integration into
the recipient genome. However, this was allayed by Okita
et al. [32] producing virus-free IPS cells from embryonic
ﬁbroblasts. Another concern is the time frame taken for
extended ex vivo culture to produce suﬃcient number
of IPS cells from ﬁbroblasts. Due to the availability in
larger numbers, ASCs-derived IPS cells have the potential to
address this issue.
Human embryonic stem cells (ESCs), isolated by Thom-
son et al. [33], have unlimited potential for proliferation in
vitro and they can form any tissue in the body [34]. ESCs
are commonly derived from the inner cell mass (ICM) of
preimplantation stage blastocysts [34]. They can be either
feeder dependent or independent. Due to the exposure of
ESCs to animal components, they pose a serious risk of
transmitting serious pathogens, and thus extensive screening
is warranted prior to therapeutic applications.
Bone formation is further controlled by engineering
adult stem cells to express genes like bone morphogenetic
proteins (BMP2, BMP4, and BMP7), core binding factor
α1 (Cbfa1), vascular endothelial growth factor (VEGF), and
noggin [35]. In addition, human bone marrow osteoprogen-
itorcellscanbeisolatedandenrichedusingmonoclonalanti-
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fraction, SB-10 (reacting with ALCAM), SH-2 (reacting
with CD105), and HOP-26 (reacting with CD63) [12, 13].
Fibroblast growth factor-2 (FGF-2) supplementation to the
culture medium promotes cell proliferation and maintains
their multilineage potential during expansion [14]. These
cells can be combined with a suitable scaﬀold and used as an
alternative to conventional bone autograft. The transplanted
osteogenic stem cells can immediately begin to proliferate
and lay down new bone matrix without removing the old
matrix present in the autograft. The development of these
cell-based technologies may result in decreased use of dead
bone from conventional bone banks to induce new bone
formation.
3. Scaffold
Akeycomponentintissueengineeringforboneregeneration
is the scaﬀo l dt h a ts e r v e sa sat e m p l a t ef o rc e l li n t e r a c t i o n s
and the formation of bone extra cellular matrix to provide
structural support to the newly formed tissue [6, 7].
Mesenchymal stem cells alone are unlikely to be suﬃcient for
bone regeneration. Although marrow injections are simple
and provide a reduced risk of morbidity, for large skeletal
defects, a scaﬀold of appropriate shape, size, and mechanical
competence is required for bone reconstruction [2]. The use
of the scaﬀold or matrix is not only in controlling growth
factor and cell delivery but also to provide a structural
template to ﬁll the tissue lesion [22]. Ideally, the scaﬀold
should facilitate cell inﬁltration, matrix deposition, and
cell attachment and consist of osteoconductive materials
such as bone protein and hydroxyapatite. They should be
able to allow load bearing and stimulate osteogenesis. The
scaﬀolds could be naturally occurring, synthetic polymers,
or bioceramics. Biodegradable scaﬀolds provide the initial
structure and stability for tissue formation but degrade as
tissue forms, providing background for matrix deposition
and tissue growth [15–18]. They can be used alone or
in combination with growth factors or osteoconductive
materials [7].
The scaﬀold aims to mimic the extracellular matrix in
a regenerating bone environment. It has to be informative
t ot h ec e l l sa sw e l la sp r o v i d em e c h a n i c a ls u p p o r t[ 7].
A biomaterial should easily integrate with the adjacent
bone and favour new tissue ingrowth (osteoconduction).
It should allow colonization by the host blood vessels, be
biocompatible and resorbable.
Various synthetic biomaterials like inorganic ceram-
ics (e.g., hydroxyapatite, coralline-derived hydroxyapatite,
tricalcium phosphate, calcium sulphates, glass ceramics,
calcium phosphate-based cements, and bioglass), metals,
and synthetic biodegradable polymer composites have been
investigated for their potential as bone scaﬀold materials.
Calcium-phosphate ceramics were introduced more than 40
years ago as bone substitutes. The most common types of
calcium-phosphate materials investigated for synthetic bone
scaﬀold development are hydroxyapatite (HA), tricalcium
phosphate (TCP), biphasic calcium phosphates (BCP), and
bioglasses. From a functional perspective, you can divide
these into rapidly resorbing, slowly resorbing, and injectable
ceramics. TCP is a classic example of rapidly resorbing
ceramic; it has got greater solubility than HA. Due to their
porosity, TCP granules are a better option than the bulk
form [35], while HA resorbs slowly, which is clinically
a disadvantage. Composite modiﬁcation of HA matrices
has been tried to increase the resorption, for example,
composite of HA and calcium carbonate and BCP. Injectable
calcium phosphate cements were also in vogue. They are
mainly composed of α-TCP, dibasic dicalcium phosphate
and tetra calcium phosphate. Clinically, they have been used
in treatment of distal radius fractures [35–37]. The main
disadvantage of their clinical relevance as synthetic bone
scaﬀolds is due to their inherent brittleness [38].
However, due to their physiochemical properties, bio-
compatibility, and controllable biodegradability, polymers
have emerged as the principal material in bone tis-
sue engineering. The most frequently investigated poly-
mers are polylactic acid (PLA) and polyglycolic acid
(PGA) [39–41]. Numerous polymers were used as scaf-
fold materials in the past decade for bone regeneration
like poly(a-hydroxy esters), poly(ethylene glycol), polydiox-
anone, poly(orthoesters), polyanhydrides, polyurethanes,
and poly(propylene fumarate) [42]. To gain more control
over the degradation rate, hydrophobicity, crystallinity,
and biological functionality, researchers designed composite
polymers in a chemical process called copolymerization
where multiple constituents are combined resulting in a
new material with desirable properties from each constituent
[43]. Undoubtedly, the most commonly utilized copolymer
for bioactive molecule encapsulation and release for bone
tissue engineering is the copolymer poly(lactic acid-co-
glycolic acid) (PLGA) [43]. The inherent deﬁciency of the
compressive modulus in polymers may be reduced through
integration of high modulus micro- and/or nanoscale
constituents within the polymer matrix [43]. The most
commonly researchedconstituent in polymer composites for
bone scaﬀolds is micro- or nanoscale HA particles [44, 45].
Tensile strength, modulus, and crack resistance of poly-
mers are improved by dispersing high modulus micro- or
nanoscale constituents [15–17, 46]. Whereas drawbacks for
utilizing natural polymers like collagen, glycosaminoglycan,
ﬁbrin,andsilkincludeinfection,ﬁxeddegradationrates,and
immunogenicity. Gel-like matrices such as ﬁbrin have been
used for cell immobilization in combination with other scaf-
folds [47]. Currently, computer-assisted design/computer-
assisted manufacturing (CAD/CAM) and rapid prototyping
techniques allow the generation of custom-made scaﬀolds
for cell delivery that ﬁt into certain bone defects [22, 48].
There is a large number of osteogenic proteins that stim-
ulate proliferation and diﬀerentiation of osteogenic cells in
vitro and in vivo. Some osteogenic factors have been cloned
and are commercially available as recombinant proteins. The
most potent osteoinductive factors are bone morphogenetic
protein (BMP). BMPs belong to the TGF-β family [49].
BMP-2 and BMP-7 are being clinically applied for fractures
and nonunions [8, 50]. They have a short half-life, so local
BMP delivery systems either require a high concentration
bolus dose or sustained delivery for bone tissue engineering
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with increased osteoclastic activity and bone resorption [23,
24]. Other options are the direct implantation of a carrier
that allows slow release or gene-based therapies, where a
transgene for BMP expression is delivered to progenitor cells
[52, 53]. Collagen carriers have historically been and remain
the primary delivery system for BMPs to clinical defects.
Because collagen has got poor BMP retention, higher BMP
drug concentrations are required. Another concern is the
potential for an immunogenic response or disease transfer
from animal-derived collagen (e.g., variants of Creutzfeldt-
Jacobdiseaseorotherprion-relateddiseases)[54].Anumber
of synthetic biomaterials have been proposed for BMP, such
as inorganic ceramics, metals, and synthetic biodegradable
polymers. Many of these materials are poorly biodegradable
and radiopaque, whereas synthetic biodegradable polymers
are mouldable and radiolucent. These characteristics make it
easier to assess radiographic growth [55, 56].
Tissue engineering strategies aim at controlling the
behaviour of individual cells to stimulate tissue formation.
Currently, tissue-engineered bone is constructed using a
perfusion bioreactor in vitro. Several diﬀerent bioreactors
have been investigated for tissue-engineering applications.
Among these bioreactors are the spinner ﬂask rotating wall
vessel reactors and the ﬂow perfusion culture bioreactors.
Flow perfusion culture oﬀers several advantages, notably
the ability to mitigate both external and internal diﬀusional
limitations as well as to apply mechanical stress to the
cultured cells. In the perfusion culture, ﬂuid ﬂow can exert
shear stress on the cells seeded on scaﬀold, improving
the mass transport of the cells. Bioreactor systems of a
variety of designs have also been utilized to enhance the in
vitro performance of osteogenic cells before implantation.
Bioreactors simulate the 3D dynamic and mechanical in vivo
environment and are designed to provide cells seeded deep
within a scaﬀold with all necessary nutrients and biological
cues to survive, proliferate, diﬀerentiate, and produce ECM
[57, 58]. Sikavitsas et al. [59] demonstrated proof of this
concept by showing that after 16 days of culture, MSC-
produced ECM was uniformly distributed in 3D scaﬀolds
cultured in a ﬂow profusion bioreactor, whereas the ECM
was limited to the periphery in the case of standard static
culture condition. Janssen et al. [60] demonstrated that
direct perfusion bioreactor system is capable of producing
clinically relevant volumes of tissue-engineered bone in a
bioreactor system, which can be monitored on line during
cultivation.
In summary, many factors can inﬂuence the osteoblastic
diﬀerentiation of marrow stromal cells when cultivated on
three-dimensional tissue engineering scaﬀolds. In creating
ideal bone tissue engineering constructs consisting of a
combination of a scaﬀold, cells, and bioactive factors, a
ﬂow perfusion bioreactor is a much more suitable culture
environmentthanstaticcultureinwellplates.Thebioreactor
eliminates mass transport limitations to the scaﬀold interior
and provides mechanical stimulation to the seeded cells
through ﬂuid shear [61]. Scaﬀold properties such as pore
size impact cell diﬀerentiation, especially in ﬂow perfusion
culture. In addition, the bone-like ECM created by the in
vitro culture of marrow stromal cells on porous scaﬀolds
creates an osteoinductive environment for the diﬀerentiation
of other marrow stromal cell populations. Therefore, bone
tissue engineering constructs created by in vitro culture have
excellent potential for bone regeneration applications in the
clinical setting.
4. ClinicalOutcomes
In literature, there are numerous studies demonstrating the
eﬀectiveness of bone tissue engineering techniques in the
rodent model; however, little has been produced demon-
strating its role in reconstructing osseous defects in larger
animals. Petite et al. [62] investigated the role of in vitro
expanded MSCs on a coral scaﬀold in large segmental bone
defects in sheep. The study compared this technique with
using the scaﬀold alone and the use of scaﬀolds with fresh
bone marrow. With the tissue-engineered technique, clinical
union was demonstrated in three out of seven bone defects,
compared with no evidence of clinical union in any of the
defects that were left empty or ﬁlled with scaﬀold alone.
With regards to the use of tissue engineering strategies in
human bone reconstruction, published literature is sparse.
Schimming and Schmelzeisen [63] reported the use of
periosteum-derived tissue-engineered bone for the augmen-
tation of the posterior maxilla. At three-month followup,
eighteen out of twenty-seven patients demonstrated an
excellent clinical, radiological, and histological outcome.
Marcacci et al. [64] reported the use of ex vivo expanded
bone marrow-derived MSCs implanted on a macroporous
hydroxyapatite scaﬀold in four patients with large bone
defects. One patient had a four-centimetre bone defect of
the mid-diaphysis of the tibia following unsuccessful bone
lengthening, another had traumatic loss of four centimetres
of bone from the distal diaphysis of the ulna, the third
patient had a seven centimetres bone defect of the humerus
following a fracture and the ﬁnal patient had six centimetres
of traumatic bone loss from the ulna. The scaﬀolds were of
theshapeandsizetoﬁteachdefectwhenimplanted.External
ﬁxation was used for mechanical stability and removed after
6.5 months for the ﬁrst patient, at 6 months for the second
patient, at 13 months in the fourth patient, and 7 months
for the ﬁnal patient. Abundant callus formation along the
implants and good integration with the host bones were
evident on radiography and computed tomography after 1-2
months. At a minimum of 1-year followup, good integration
of the implant to host bone was evident. All the patients
reported favourable limb function outcome [64].
5. Conclusion
The use of tissue engineering for the reconstruction of
bone defects has exciting potential; however, there is much
work to be done before this strategy can be considered a
serious clinical option [65–71]. The majority of research in
MSC-based bone reconstruction has looked at isolation and
expansion in vitro of MSCs, their delivery to defect sites
and techniques to improve proliferation potential, and direct
the MSCs towards osteogenesis using the appropriate factors
[72–86].Stem Cells International 5
Whilst animal studies have proven to show some success,
theuseoftissueengineeringtorepairbonedefectsinhumans
remains a challenge with limited clinical data. The reason for
the perceived failure of these strategies in humans is thought
toliewithaninadequatevascularsupply,leadingtocelldeath
of implanted cells. There have also been concerns raised
by the poor resorbability of the scaﬀolds and instability of
the scaﬀold ﬁxation. Whilst much work has been done on
the factors involved in tissue engineering, more study is
required to improve the key factor of cell survival in human
models, such as improving nutrient and oxygen supply.
Eventually, randomised controlled trials will be required to
determine the eﬀectiveness of tissue engineering approaches
to bone reconstruction in humans before clinical use can be
considered a viable option.
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